Hughss S W, Burley D M
Postgrad Med J. 1970 Jul;46(537):409-16. doi: 10.1136/pgmj.46.537.409.
Aminoglutethimide was introduced as an anti-convulsant drug in the U.S.A. in 1960. The occurrence of a number of side-effects, including several endocrine effects such as goitrogenesis, sexual precocity and virilization, led to its withdrawal. Further investigation indicated that the drug inhibited adrenal biosynthesis, particularly of aldosterone, cortisol and androgens, probably by interfering with the conversion of cholesterol to delta-5-pregnenolone. Aminoglutethimide has also been shown to modify the extra-adrenal metabolism of cortisol. The possible clinical applications of these ‘side-effects’ are discussed.
1960年,氨鲁米特作为一种抗惊厥药物在美国被引入。由于出现了许多副作用,包括一些内分泌方面的影响,如甲状腺肿形成、性早熟和男性化,该药物被停用。进一步研究表明,该药物抑制肾上腺生物合成,特别是醛固酮、皮质醇和雄激素的合成,可能是通过干扰胆固醇向δ-5-孕烯醇酮的转化。氨鲁米特还被证明可以改变皮质醇的肾上腺外代谢。本文讨论了这些“副作用”可能的临床应用。